<DOC>
	<DOCNO>NCT00523484</DOCNO>
	<brief_summary>This study observational study see whether anxiety level correlate PSA level current practice patient prostate cancer take hormonal therapy . For assessment anxiety level BAI ( Beck Anxiety Inventory ) use . The target population study patient prostate cancer diagnose previously take hormonal therapy regular follow-up PSA test . The follow-up duration total 6 month interim visit 3 month final visit 6 month .</brief_summary>
	<brief_title>Casodex/Zoladex Hormonal therApy Study assessMent Correlation Between PSA &amp; BAI prOstate Cancer patieNts</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>1 . Provision write informed consent 2 . Patients take PSA test regularly 3 . Observation suitable patient PSA change accord hormonal treatment least 6months 4 . Locally advanced advanced prostate cancer patient suitable hormonal therapy 5 . Prostate Cancer Patients take one treatment among 3 hormonal therapy : Bicalutamide Monotherapy : Bicalutamide 150mg/day Goserelin 3.6mg/10.8mg MAB ( Maximal Androgen Blockade ) : Bicalutamide 50mg + Goserelin 3.6/10.8mg 1 . Prohibition use permit indication 2 . Previous inclusion present study 3 . Participation clinical study last 30 day</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Beck Anxiety Inventory</keyword>
	<keyword>Prostate Cancer</keyword>
	<keyword>Prostate Specific Antigen</keyword>
	<keyword>Naturalistic</keyword>
	<keyword>Observational</keyword>
</DOC>